Merck Exceeds Q3 Earnings Estimates and Raises 2026 Profit Outlook
Merck (MRK) reported third-quarter non-GAAP earnings of $2.49 per share, surpassing Wall Street expectations. The company's strong performance was primarily driven by robust sales of its oncology blockbuster Keytruda alongside growth in its newer pharmaceutical products. Following the positive quarterly results, Merck raised its full-year 2026 profit outlook. This upward revision reflects management's confidence in the sustained commercial momentum of its core drug portfolio and its ability to drive long-term value for shareholders.
Tickers: $MRK
Topics: earnings beat Keytruda sales pharmaceuticals profit outlook